FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

62 letters match. Newest first.

  1. Lovelace Biomedical Research Institute

    Lovelace Biomedical's quality unit failed to ensure final drug study reports matched raw data, FDA says.

    Medium
  2. Maria E. De La Torre Silva, M.D.

    Clinical investigator Dr. Maria E. De La Torre Silva enrolled a subject in two drug trials and kept inadequate study-drug records.

    Medium
  3. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  4. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  5. HealthPartners Neuroscience Center Research and Innovation

    FDA warned HealthPartners Neuroscience Center that its animal studies of an investigational drug violated good laboratory practice rules.

    Medium
  6. Naseem A. Jaffrani, M.D.

    FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.

    High risk
  7. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk
  8. Ehsan Sadri, M.D.

    FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.

    High risk
  9. Vedic Lifesciences Pvt. Ltd.

    FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.

    Medium
  10. Bertrand P. Cole, D.O.

    FDA warns Dr. Bertrand P. Cole that he gave four trial subjects too much drug by not following the study plan.

    High risk
  11. Mark S. Dacey, M.D.

    FDA warns Dr. Mark S. Dacey that a trial subject underwent an optional eye-fluid sampling procedure after twice declining consent.

    High risk
  12. Center For Immunology Science, LLC

    FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.

    High risk
  13. Prodrome Sciences USA, LLC

    Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.

    High risk
  14. Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

    FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

    High risk
  15. Devalingam Mahalingam, M.D., Ph.D.

    FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.

    High risk
  16. Maria A. Carballosa, M.D.

    FDA warns Dr. Maria Carballosa over failure to retain clinical trial records for an investigational drug.

    Medium
  17. Verdure Sciences, Inc.

    FDA says Verdure Sciences ran a clinical trial of Maplifa without submitting a required IND.

    High risk
  18. Pamela K. Den Besten, DDS, MS

    FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.

    High risk
  19. Ralph A. DeFronzo, M.D.

    FDA warns Dr. Ralph A. DeFronzo for enrolling ineligible subjects and failing to promptly report study changes to the IRB.

    High risk
  20. Shirish M. Gadgeel, M.D.

    Detroit clinical investigator Dr. Shirish Gadgeel enrolled ineligible subjects and missed required consent for genetic testing in drug trials.

    High risk
  21. Mark J. Savant, M.D

    FDA warns clinical investigator Mark J. Savant, M.D., over protocol dosing and eligibility failures and missing informed consent in a drug trial.

    High risk
  22. Peter Michael, M.D.

    FDA warns clinical investigator Peter Michael, M.D. that pediatric trial subjects received twice the protocol's maximum drug dose.

    High risk
  23. American Behavioral Research Institute, LLC

    FDA warned American Behavioral Research Institute for running a 40-subject Relaxium sleep study without an IND, treating a supplement as a drug.

    High risk
  24. Amy Lightner, MD

    FDA warns sponsor-investigator Amy Lightner, MD over clinical trial violations, including dosing before eligibility tests and unreported serious adverse events.

    High risk
  25. Nana Barseghian, M.D.

    FDA warns clinical investigator Nana Barseghian for enrolling high-body-mass-index subjects in drug trials despite protocol exclusion.

    High risk
  26. Americo F. Padilla, M.D.

    FDA warns clinical investigator Americo F. Padilla, M.D. over failing to obtain parental consent before enrolling pediatric subjects in drug trials.

    High risk
  27. Mehran Michael Bahrami, M.D.

    FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.

    High risk
  28. ISOThrive, Inc.

    ISOThrive ran two human studies of a supplement used as a drug without submitting a required IND.

    High risk
  29. Han C. Phan, M.D.

    FDA warns clinical investigator Dr. Han C. Phan over failure to follow a drug study’s protocol for required tests.

    Medium
  30. Applied Therapeutics, Inc.

    Applied Therapeutics, a trial sponsor, failed to let FDA access deleted electronic trial data and omitted dosing-error information from its drug application.

    High risk
  31. Richard W. Foltin, Ph.D.

    FDA warned sponsor Dr. Richard W. Foltin for starting drug trials in people without an IND.

    High risk
  32. Julio R. Flamini, M.D./Clinical Integrative Research Center of Atlanta

    FDA warns an Atlanta clinical investigator after a 15-year-old trial subject was given about 10 times the protocol dose.

    High risk
  33. Angela D. Ritter, M.D.

    FDA warns Dr. Angela Ritter over unauthorized dosing of an investigational drug and missing ethics-board review.

    High risk
  34. Kevin R. Bender, M.D./DBC Research Corporation

    Clinical investigator Kevin R. Bender failed to secure a controlled investigational drug, and 110 kits were stolen.

    High risk
  35. Bret R. Rutherford, M.D.

    FDA warned Dr. Bret R. Rutherford for enrolling ineligible patients in two drug studies by skipping required antidepressant washout.

    High risk
  36. Jeffrey W. Taub, M.D./Children's Hospital of Michigan

    FDA warns Detroit investigator over pediatric drug trial protocol deviations and lapsed IRB approval.

    High risk
  37. Anish S. Shah, M.D./Siyan Clinical Research

    FDA warned clinical investigator Dr. Anish Shah that he broke blinding rules in a depression drug study, calling the site's data into question.

    Medium
  38. Melanie M. Hoppers, M.D./Physicians Quality Care

    FDA warns Dr. Melanie Hoppers over enrolling ineligible patients in a baloxavir marboxil influenza trial.

    High risk
  39. Samm Solutions, Inc., d.b.a. BTS Research

    Samm Solutions/BTS Research failed good laboratory practice (GLP) rules for nonclinical drug studies, FDA says.

    Medium
  40. Maria W. Greenwald, M.D.

    FDA warned Dr. Maria W. Greenwald over clinical trial violations involving investigational drugs, including ineligible subjects and inaccurate records.

    High risk
  41. Antonio E. Blanco, M.D./Vista Health Research, LLC

    FDA cited Dr. Antonio E. Blanco/Vista Health Research for enrolling ineligible trial subjects and missing required safety imaging.

    High risk
  42. Luis Javier Pena-Hernandez, M.D., FCCP

    FDA warns Dr. Pena-Hernandez over ineligible subject enrollment and lapsed IRB approval for investigational drugs.

    High risk
  43. Angela M. Stupi, M.D.

    Clinical investigator Angela M. Stupi, M.D. enrolled ineligible subjects and injected study drug at wrong body sites in two trials.

    High risk
  44. Randy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.

    FDA warns Dr. Epstein/Chicago Cornea Consultants over trial without IND and inadequate drug records.

    High risk
  45. Mobeen Mazhar, M.D.

    FDA warned clinical investigator Dr. Mobeen Mazhar for enrolling ineligible subjects, missing safety reports, and consenting a subject late in drug trials.

    High risk
  46. Tyrone L. McCall, M.D./Cornea Associates of Texas

    FDA warns Dallas eye practice Cornea Associates for running a 69-subject drug study without an IND.

    High risk
  47. Robert J. Hayashi, M.D./Washington University School of Medicine, Department of Pediatrics

    FDA warned Dr. Robert J. Hayashi over protocol deviations in pediatric drug trials that exposed a child to unnecessary study drug and invasive procedures.

    High risk
  48. Maggie Jeffries, M.D. / Avanti Anesthesiology, LLC

    FDA warns Houston clinical investigator Dr. Maggie Jeffries for running drug trials without an IND and with informed-consent failures.

    High risk
  49. Adarsh Daswani, M.D.

    Clinical investigator Adarsh Daswani, M.D. failed to follow protocol dosing and oversight for an investigational drug study.

    High risk
  50. "David M. Lubeck, M.D./Arbor Centers for EyeCare

    FDA warned Dr. David Lubeck for running a combination-drug study without an IND and enrolling five subjects.

    High risk